Form 4: VYNE Therapeutics CEO David Domzalski Reports Stock Transaction
SEC Form 4 Filing
David Domzalski, CEO of VYNE Therapeutics, reports the disposal of 1,004 common stock shares to cover tax obligations related to vesting restricted stock units on April 1, 2024.
Summary
- On April 1, 2024, David Domzalski, the President and CEO of VYNE Therapeutics Inc., disposed of 1,004 shares of common stock.
- The transaction was executed to satisfy tax withholding requirements related to the vesting of restricted stock units.
- The shares were disposed of at a price of $3.08 per share.
- Following the transaction, Domzalski directly owns 494,160 shares of VYNE Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to a routine stock transaction for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is related to tax obligations from vested stock, which is a common occurrence.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock transaction where 1,004 shares were disposed of to cover tax obligations. |
| 04/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.